MiR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation

Cancer Research

Volumn 73, Issue 13, 2013, Pages 4098-4111

  Penna, Elisa ^a,b   Orso, Francesca ^a,b   Cimino, Daniela ^a,b   Vercellino, Irene ^a,b   Grassi, Elena ^a,b   Quaglino, Elena ^a,b   Turco, Emilia ^a,b   Taverna, Daniela ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Department of Molecular Biotechnology and Health Sciences ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; MICRORNA; MICRORNA 148B; MICRORNA 214; TRANSCRIPTION FACTOR AP 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA METASTASIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIGENS, CD; BASE SEQUENCE; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MELANOMA; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84880048722     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3686     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55: 74-108.
2. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003;3: 559-70.
3. Melnikova VO, Bar-Eli M. Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 2008;7: 997-1003.
4. Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 1995;181: 2213-20.
5. Swart GW, Lunter PC, Kilsdonk JW, Kempen LC. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev 2005;24: 223-36.
6. Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics 2010;7: 231-43.
7. Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res 2008;151: 122-8.
8. van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP, Swart GW. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol 2000;156: 769-74.
9. van Kilsdonk JW, Wilting RH, Bergers M, van Muijen GN, Schalkwijk J, van Kempen LC, et al. Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule. Cancer Res 2008;68: 3671-9.
10. Jannie KM, Stipp CS, Weiner JA. ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells. PLoS ONE 2012;7: e39330.
11. Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M, Willems PH, et al. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 2005;65: 8801-8.
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136: 215-33.
13. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9: 102-14.
14. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10: 704-14.
15. Valastyan S, Weinberg RA. MicroRNAs: crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle 2009; 8: 3506-12.
16. Mueller DW, Bosserhoff AK. Role of miRNAs in the progression of malignant melanoma. Br J Cancer 2009;101: 551-6.
17. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008;6: 760-9.
18. Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011;30: 1990-2007.
19. Circosta P, Granziero L, Follenzi A, Vigna E, Stella S, Vallario A, et al. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum Gene Ther 2009;20: 1576-88.
20. Primo L, di Blasio L, Roca C, Droetto S, Piva R, Schaffhausen B, et al. Essential role of PDK1 in regulating endothelial cell migration. J Cell Biol 2007;176: 1035-47.
21. Poliseno L, Haimovic A, Christos PJ, Vega Y, Saenz de Miera EC, Shapiro R, et al. Deletion of PTENP1 pseudogene in human melanoma. J Invest Dermatol 2011;131: 2497-500.
22. Venesio T, Chiorino G, Balsamo A, Zaccagna A, Petti C, Scatolini M, et al. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol 2008;21: 716-26.
23. Stormo GD, Fields DS. Specificity, free energy and information content in protein-DNA interactions. Trends Biochem Sci 1998;23: 109-13.
24. Orso F, Cora D, Ubezio B, Provero P, Caselle M, Taverna D. Identification of functional TFAP2A and SP1 binding sites in new TFAP2Amodulated genes. BMC Genomics 2010;11: 355.
25. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A 2007; 104: 17719-24.
26. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004;10: 1507-17.
27. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are micro-RNA targets. Cell 2005;120: 15-20.
28. Tang R, Li L, Zhu D, Hou D, Cao T, Gu H, et al. Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system. Cell Res 2012;22: 504-15.
29. The ENCODE Project Consortium. The ENCODE (ENCyclopedia Of DNA Elements) project. Science 2004;306: 636-40.
30. Osella-Abate S, Novelli M, Quaglino P, Orso F, Ubezio B, Tomasini C, et al. Expression of AP-2alpha, AP-2gamma and ESDN in primary melanomas: correlation with histopathological features and potential prognostic value. J Dermatol Sci 2012;68: 202-4.
31. Cimino D, Fuso L, Sfiligoi C, Biglia N, Ponzone R, Maggiorotto F, et al. Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Int J Cancer 2008;123: 1327-38.
32. Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR, et al. Activated leukocyte cell adhesion molecule (CD166) - its prognostic power for colorectal cancer patients. J Surg Res 2012;177: e15-20.
33. Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, et al. Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients. BMC Cancer 2012;12: 140.
34. Witzel I, Schroder C, Muller V, Zander H, Tachezy M, Ihnen M, et al. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis. Oncology 2012;82: 305-12.
35. Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR, et al. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS ONE 2012;7: e39018.
36. Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V, Pantel K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat 2012;134: 933-41.
37. Masedunskas A, King JA, Tan F, Cochran R, Stevens T, Sviridov D, et al. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett 2006;580: 2637-45.
38. King JA, Tan F, Mbeunkui F, Chambers Z, Cantrell S, Chen H, et al. Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer. Mol Cancer 2010;9: 266.
39. Tan F, Ghosh S, Mbeunkui F, Thomas R, Weiner JA, Ofori-Acquah SF. Essential role for ALCAM gene silencing in megakaryocytic differentiation of K562 cells. BMC Mol Biol 2010;11: 91.
40. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001;14: 78-85.
41. Bauer R, Imhof A, Pscherer A, Kopp H, Moser M, Seegers S, et al. The genomic structure of the human AP-2 transcription factor. Nucleic Acids Res 1994;22: 1413-20.
42. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998;273: 16501-8.
43. Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008;214: 17-24.
44. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol 2009;129: 1740-51.
45. Cimino D, De Pitta C, Orso F, Zampini M, Casara S, Penna E, et al. miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J 2013;27: 1223-35.